SCHEMBL1471317

SCHEMBL1471317

COc1cccc(N2C(=O)C=C(c3ccc(Cl)cc3)C2=O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.52
MAPT P10636 7/20 0.50
ALDH1A1 P00352 6/20 0.50
MEN1 O00255 1/20 0.50
MAPK1 P28482 1/20 0.50
KMT2A Q03164 1/20 0.50
NR1H3 Q13133 1/20 0.45
TP53 P04637 1/20 0.44
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43
HSD17B10 Q99714 1/20 0.43
LMNA P02545 3/20 0.42
NPSR1 Q6W5P4 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
HTT P42858 2/20 0.42
KDM4E B2RXH2 1/20 0.42
RAB9A P51151 1/20 0.42
CACNA1B Q00975 2/20 0.42
APBA1 Q02410 2/20 0.42
HCRTR1 O43613 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1471712 0.90 MAPT (0.62) MGLLMAPTALDH1A1MEN1MAPK1
SCHEMBL1471803 0.88 MGLL (0.56) MGLLMAPTALDH1A1MEN1MAPK1
SCHEMBL1471117 0.86 MGLL (0.53) MGLLMAPTALDH1A1MEN1MAPK1
SCHEMBL1473614 0.85 MGLL (0.49) MGLLMAPTALDH1A1MEN1MAPK1
SCHEMBL1471785 0.85 MGLL (0.49) MGLLMAPTALDH1A1MEN1MAPK1
SCHEMBL1471125 0.84 HSP90AA1 (0.50) MGLLMAPTALDH1A1MEN1MAPK1
SCHEMBL1473349 0.80 MAPT (0.57) MGLLMAPTALDH1A1MEN1KMT2A
SCHEMBL1471051 0.80 MAPT (0.49) MGLLMAPTALDH1A1MEN1MAPK1
SCHEMBL1471837 0.80 MAPT (0.51) MGLLMAPTALDH1A1MEN1MAPK1
SCHEMBL1470995 0.79 MAPT (0.60) MGLLMAPTALDH1A1MEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915304-B2 Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT CONGENIA S.R.L. (IT) 2011-03-29 US disclosed
EP-2091531-B1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S R L (IT) 2010-11-24 EP disclosed
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2010-04-22 US disclosed
EP-2091531-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT Congenia S.r.l. (IT) 2009-08-26 EP disclosed
WO-2008067863-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CYC1, MTPN, TXN2 MGLL 857/4885MAPT 1947/4885ALDH1A1 800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.